1
|
Tardieu M, Cudejko C, Cano A, Hoebeke C, Bernoux D, Goetz V, Pichard S, Brassier A, Schiff M, Feillet F, Rollier P, Mention K, Dobbelaere D, Fouilhoux A, Espil-Taris C, Eyer D, Huet F, Walther-Louvier U, Barth M, Chevret L, Kuster A, Lefranc J, Neveu J, Pitelet G, Ropars J, Rivier F, Roubertie A, Touati G, Vanhulle C, Tardieu E, Caillaud C, Froissart R, Champeaux M, Labarthe F, Chabrol B. Long-term follow-up of 64 children with classical infantile-onset Pompe disease since 2004: A French real-life observational study. Eur J Neurol 2023; 30:2828-2837. [PMID: 37235686 DOI: 10.1111/ene.15894] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Revised: 04/21/2023] [Accepted: 05/22/2023] [Indexed: 05/28/2023]
Abstract
BACKGROUND Classical infantile-onset Pompe disease (IOPD) is the most severe form of Pompe disease. Enzyme replacement therapy (ERT) has significantly increased survival but only a few studies have reported long-term outcomes. METHODS We retrospectively analyzed the outcomes of classical IOPD patients diagnosed in France between 2004 and 2020. RESULTS Sixty-four patients were identified. At diagnosis (median age 4 months) all patients had cardiomyopathy and most had severe hypotonia (57 of 62 patients, 92%). ERT was initiated in 50 (78%) patients and stopped later due to being ineffective in 10 (21%). Thirty-seven (58%) patients died during follow-up, including all untreated and discontinued ERT patients, and 13 additional patients. Mortality was higher during the first 3 years of life and after the age of 12 years. Persistence of cardiomyopathy during follow-up and/or the presence of heart failure were highly associated with an increased risk of death. In contrast, cross-reactive immunologic material (CRIM)-negative status (n = 16, 26%) was unrelated to increased mortality, presumably because immunomodulation protocols prevent the emergence of high antibody titers to ERT. Besides survival, decreased ERT efficacy appeared after the age of 6 years, with a progressive decline in motor and pulmonary functions for most survivors. CONCLUSIONS This study reports the long-term follow-up of one of the largest cohorts of classical IOPD patients and demonstrates high long-term mortality and morbidity rates with a secondary decline in muscular and respiratory functions. This decreased efficacy seems to be multifactorial, highlighting the importance of developing new therapeutic approaches targeting various aspects of pathogenesis.
Collapse
Affiliation(s)
- Marine Tardieu
- Centre de Référence des Maladies Héréditaires du Métabolisme ToTeM, Service de Médecine Pédiatrique, Hôpital Clocheville, Tours, France
| | - Céline Cudejko
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurométabolisme Pédiatrique, Hôpital Timone Enfants, AP-HM, Marseille, France
| | - Aline Cano
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurométabolisme Pédiatrique, Hôpital Timone Enfants, AP-HM, Marseille, France
| | - Célia Hoebeke
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurométabolisme Pédiatrique, Hôpital Timone Enfants, AP-HM, Marseille, France
| | - Delphine Bernoux
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurométabolisme Pédiatrique, Hôpital Timone Enfants, AP-HM, Marseille, France
| | - Violette Goetz
- Centre de Référence des Maladies Héréditaires du Métabolisme ToTeM, Service de Médecine Pédiatrique, Hôpital Clocheville, Tours, France
| | - Samia Pichard
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Métabolisme Pédiatrique, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Anaïs Brassier
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Métabolisme Pédiatrique, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Manuel Schiff
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Métabolisme Pédiatrique, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - François Feillet
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Médecine Infantile, Hôpital Brabois Enfants; Unité INSERM NGERE U 1256, Campus Babrois-Santé, Vandœuvre-lès-Nancy, France
| | - Paul Rollier
- Service de Génétique Clinique, Site Hôpital Sud, Rennes, France
| | - Karine Mention
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service Néphrologie, Endocrinologie, Maladies Métaboliques et Hématologie Pédiatrique, Hôpital Jeanne de Flandre, Lille, France
| | - Dries Dobbelaere
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service Néphrologie, Endocrinologie, Maladies Métaboliques et Hématologie Pédiatrique, Hôpital Jeanne de Flandre, Lille, France
| | - Alain Fouilhoux
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service d'Endocrinologie et de Diabétologie Pédiatriques et Maladies Héréditaires du Métabolisme, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
| | - Caroline Espil-Taris
- Centre de Référence des Maladies Neuromusculaires AOC, Service de Neuropédiatrie, Hôpital des Enfants Pellegrin, Bordeaux, France
| | - Didier Eyer
- Service des Maladies Métaboliques, Hôpital de Hautepierre, Strasbourg, France
| | - Frédéric Huet
- Centre de Compétence des Maladies Héréditaires du Métabolisme, Service de Pédiatrie Multidisciplinaire, Hôpital d'Enfants, Dijon, France
| | - Ulrike Walther-Louvier
- Centre de Référence des Maladies Neuromusculaires AOC, Service de Neuropédiatrie, Hôpital Gui de Chauliac, Montpellier, France
| | - Magalie Barth
- Centre de Compétence des Maladies Héréditaires du Métabolisme, Service de Génétique, CHU Angers, Angers, France
| | - Laurent Chevret
- Service Pédiatrie et Urgences Pédiatriques, CH Saint-Brieuc, Saint-Brieuc, France
| | - Alice Kuster
- Centre de Compétence des Maladies Héréditaires du Métabolisme, Service de Réanimation Pédiatrique, CHU Nantes, Nantes, France
| | | | - Julien Neveu
- Service de Neuropédiatrie, Hôpitaux Pédiatriques de Nice, CHU Lenval, Nice, France
| | - Gaele Pitelet
- Service de Neuropédiatrie, Hôpitaux Pédiatriques de Nice, CHU Lenval, Nice, France
| | - Juliette Ropars
- Centre de Référence Maladies Neuromusculaires AOC, Service de Neuropédiatrie, Hôpital Morvan, Brest, France
| | - François Rivier
- Centre de Référence des Maladies Neuromusculaires AOC, Service de Neuropédiatrie, Hôpital Gui de Chauliac, Montpellier, France
- PhyMedExp, Université de Montpellier, INSERM, CNRS, Montpellier, France
| | - Agathe Roubertie
- Centre de Compétence des Maladies Héréditaires du Métabolisme, Service de Neurologie Pédiatrique, Hôpital Gui de Chauliac; INM, INSERM U 1298, Université de Montpellier, Montpellier, France
| | - Guy Touati
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Gastro-entérologie, Hépatologie, Nutrition et Maladies Héréditaires du Métabolisme Pédiatrique, Hôpital des Enfants, Toulouse, France
| | - Catherine Vanhulle
- Service de Néonatalogie et Réanimation Pédiatrique, Hôpital Charles Nicolle, Rouen, France
| | - Emilie Tardieu
- Service de Santé Universitaire, Université Lumière Lyon 2, Lyon, France
| | - Catherine Caillaud
- Service de Biochimie Métabolique, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Roseline Froissart
- Service de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Bron, France
| | - Murielle Champeaux
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurométabolisme Pédiatrique, Hôpital Timone Enfants, AP-HM, Marseille, France
| | - François Labarthe
- Centre de Référence des Maladies Héréditaires du Métabolisme ToTeM, Service de Médecine Pédiatrique, Hôpital Clocheville, Tours, France
- Inserm U1069, N2C, Université de Tours, Tours, France
| | - Brigitte Chabrol
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurométabolisme Pédiatrique, Hôpital Timone Enfants, AP-HM, Marseille, France
| |
Collapse
|
2
|
Guasto A, Dubail J, Aguilera-Albesa S, Paganini C, Vanhulle C, Haouari W, Gorría-Redondo N, Aznal-Sainz E, Boddaert N, Planas-Serra L, Schlüter A, Verdura E, Bruneel A, Rossi A, Huber C, Pujol A, Cormier-Daire V. Biallelic variants in SLC35B2 cause a novel chondrodysplasia with hypomyelinating leukodystrophy. Brain 2022; 145:3711-3722. [PMID: 35325049 DOI: 10.1093/brain/awac110] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Revised: 02/22/2022] [Accepted: 03/13/2022] [Indexed: 11/13/2022] Open
Abstract
Sulfated proteoglycans are essential in skeletal and brain development. Recently, pathogenic variants in genes encoding proteins involved in the proteoglycan biosynthesis have been identified in a range of chondrodysplasia associated with intellectual disability. Nevertheless, several patients remain with unidentified molecular basis. This study aimed to contribute to the deciphering of new molecular bases in patients with chondrodysplasia and neuro-developmental disease. Exome sequencing was performed to identify pathogenic variants in patients presenting with chondrodysplasia and intellectual disability. The pathogenic effects of the potentially causative variants were analyzed by functional studies. We identified homozygous variants (c.1218_1220del and c.1224_1225del) in SLC35B2 in two patients with pre- and postnatal growth retardation, scoliosis, severe motor and intellectual disabilities and hypomyelinating leukodystrophy. By functional analyses, we showed that the variants affect SLC35B2 mRNA expression and protein subcellular localization leading to a functional impairment of the protein. Consistent with those results, we detected proteoglycan sulfation impairment in SLC35B2 patient fibroblasts and serum. Our data support that SLC35B2 functional impairment causes a novel syndromic chondrodysplasia with hypomyelinating leukodystrophy, most likely through a proteoglycan sulfation defect. This is the first time that SLC35B2 variants are associated with bone and brain development in human.
Collapse
Affiliation(s)
- Alessandra Guasto
- Paris Cité University, INSERM UMR1163, Imagine Institute, 75015 Paris, France
| | - Johanne Dubail
- Paris Cité University, INSERM UMR1163, Imagine Institute, 75015 Paris, France
| | - Sergio Aguilera-Albesa
- Pediatric Neurology Unit, Department of Pediatrics, Complejo Hospitalario de Navarra, Navarrabiomed, Pamplona, Spain.,Children's Medically Complex Diseases Unit, Department of Pediatrics, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - Chiara Paganini
- Department of Molecular Medicine, Unit of Biochemistry, University of Pavia, Pavia, Italy
| | - Catherine Vanhulle
- Service de Neuropédiatrie, pavillon Martainville, Hôpital Charles Nicolle, 76031, Rouen, France
| | - Walid Haouari
- INSERM UMR1193, Paris-Saclay University, F-92220 Châtenay-Malabry, France
| | - Nerea Gorría-Redondo
- Pediatric Neurology Unit, Department of Pediatrics, Complejo Hospitalario de Navarra, Navarrabiomed, Pamplona, Spain
| | - Elena Aznal-Sainz
- Children's Medically Complex Diseases Unit, Department of Pediatrics, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - Nathalie Boddaert
- Service d'Imagerie pédiatrique, AP-HP, Hôpital Necker-Enfants malades, F-75015 Paris, France
| | - Laura Planas-Serra
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.,Centre for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain
| | - Agatha Schlüter
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.,Centre for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain
| | - Edgard Verdura
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.,Centre for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain
| | - Arnaud Bruneel
- INSERM UMR1193, Paris-Saclay University, F-92220 Châtenay-Malabry, France.,AP-HP, Biochimie métabolique et cellulaire, Hôpital Bichat, F-75018, Paris, France
| | - Antonio Rossi
- Department of Molecular Medicine, Unit of Biochemistry, University of Pavia, Pavia, Italy
| | - Céline Huber
- Paris Cité University, INSERM UMR1163, Imagine Institute, 75015 Paris, France
| | - Aurora Pujol
- Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Catalonia, Spain.,Centre for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029, Madrid, Spain.,Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Catalonia, Spain
| | - Valérie Cormier-Daire
- Paris Cité University, INSERM UMR1163, Imagine Institute, 75015 Paris, France.,Service de Génétique clinique, Centre de référence pour les maladies osseuses constitutionnelles, AP-HP, Hôpital Necker-Enfants malades, F-75015 Paris, France
| |
Collapse
|
3
|
Tebani A, Sudrié-Arnaud B, Dabaj I, Torre S, Domitille L, Snanoudj S, Heron B, Levade T, Caillaud C, Vergnaud S, Saugier-Veber P, Coutant S, Dranguet H, Froissart R, Al Khouri M, Alembik Y, Baruteau J, Arnoux JB, Brassier A, Brehin AC, Busa T, Cano A, Chabrol B, Coubes C, Desguerre I, Doco-Fenzy M, Drenou B, Elcioglu NH, Elsayed S, Fouilhoux A, Poirsier C, Goldenberg A, Jouvencel P, Kuster A, Labarthe F, Lazaro L, Pichard S, Rivera S, Roche S, Roggerone S, Roubertie A, Sigaudy S, Spodenkiewicz M, Tardieu M, Vanhulle C, Marret S, Bekri S. Disentangling molecular and clinical stratification patterns in beta-galactosidase deficiency. J Med Genet 2021; 59:377-384. [PMID: 33737400 DOI: 10.1136/jmedgenet-2020-107510] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 01/16/2021] [Accepted: 01/19/2021] [Indexed: 11/04/2022]
Abstract
INTRODUCTION This study aims to define the phenotypic and molecular spectrum of the two clinical forms of β-galactosidase (β-GAL) deficiency, GM1-gangliosidosis and mucopolysaccharidosis IVB (Morquio disease type B, MPSIVB). METHODS Clinical and genetic data of 52 probands, 47 patients with GM1-gangliosidosis and 5 patients with MPSIVB were analysed. RESULTS The clinical presentations in patients with GM1-gangliosidosis are consistent with a phenotypic continuum ranging from a severe antenatal form with hydrops fetalis to an adult form with an extrapyramidal syndrome. Molecular studies evidenced 47 variants located throughout the sequence of the GLB1 gene, in all exons except 7, 11 and 12. Eighteen novel variants (15 substitutions and 3 deletions) were identified. Several variants were linked specifically to early-onset GM1-gangliosidosis, late-onset GM1-gangliosidosis or MPSIVB phenotypes. This integrative molecular and clinical stratification suggests a variant-driven patient assignment to a given clinical and severity group. CONCLUSION This study reports one of the largest series of b-GAL deficiency with an integrative patient stratification combining molecular and clinical features. This work contributes to expand the community knowledge regarding the molecular and clinical landscapes of b-GAL deficiency for a better patient management.
Collapse
Affiliation(s)
- Abdellah Tebani
- Department of Metabolic Biochemistry, Rouen University Hospital, Rouen, France.,Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | | | - Ivana Dabaj
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France.,Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, Rouen, France
| | - Stéphanie Torre
- Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, Rouen, France
| | - Laur Domitille
- Pediatric Neurology Department, Robert Debré Hospital, Public Hospital Network of Paris, Paris, France
| | - Sarah Snanoudj
- Department of Metabolic Biochemistry, Rouen University Hospital, Rouen, France.,Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Benedicte Heron
- Reference Center for Lysosomal Diseases, Pediatric Neurology Department, UH Armand Trousseau-La Roche Guyon, APHP, GUEP, Paris, France
| | - Thierry Levade
- Laboratoire de Biochimie Métabolique, Institut Fédératif de Biologie, CHU Purpan, Toulouse, France.,Cancer Research Center, INSERM UMR1037 CRCT, Toulouse, France
| | - Catherine Caillaud
- Biochemistry, Metabolomic and Proteomic Department, Necker Enfants Malades University Hospital, Assistance Publique Hôpitaux de Paris, UMRS 1151, INSERM, Institute Necker Enfants Malades, Paris Descartes University, Paris, France
| | - Sabrina Vergnaud
- UF Maladies Héréditaires Enzymatiques Rares-CGD, Institut de Biologie et de Pathologies, CHU de Grenoble Alpes, Grenoble, France
| | - Pascale Saugier-Veber
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Sophie Coutant
- Department of Genetics, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F76000, Normandy Centre for Genomic and Personalized Medicine, ROUEN, France
| | - Hélène Dranguet
- Department of Metabolic Biochemistry, Rouen University Hospital, Rouen, France
| | - Roseline Froissart
- Biochemical and Molecular Biology Department, Centre de Biologie et de Pathologie Est Hospices Civils de Lyon, Lyon, France
| | - Majed Al Khouri
- Department of Pediatric Gastroenterology, hepatology and Nutrition, University hospital of Montpellier, Montpellier, France
| | - Yves Alembik
- Department of Clinical Genetic, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Julien Baruteau
- Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street Institute of Child Health, University College London, London, UK
| | - Jean-Baptiste Arnoux
- Department of Inherited Metabolic Disease, Necker-Enfants Malades University Hospital, AP-HP, Paris, France
| | - Anais Brassier
- Reference Center of Inherited Metabolic Diseases, Necker Enfants Malades Hospital, Imagine Institute, University Paris Descartes, Paris, France
| | - Anne-Claire Brehin
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France
| | - Tiffany Busa
- Département de Génétique Médicale, Hôpital Timone Enfant, Marseille, France
| | - Aline Cano
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neuropédiatrie, CHU La Timone Enfants, APHM, Marseille, France
| | - Brigitte Chabrol
- Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neuropédiatrie, CHU La Timone Enfants, APHM, Marseille, France
| | - Christine Coubes
- Genetic Services, A. de Villeneuve Hospital, Montpellier, France
| | - Isabelle Desguerre
- Department of Paediatric Neurology, Hopital universitaire Necker-Enfants malades Service de Pediatrie generale, Paris, Île-de-France, France
| | - Martine Doco-Fenzy
- Service de génétique, CHRU Reims, Reims, France.,EA3801, UFR médecine, France
| | - Bernard Drenou
- Department of Hematolog, Hôpital Emile Muller - CH de Mulhouse, Mulhouse, France
| | - Nursel H Elcioglu
- Pediatric Genetics, Marmara University Medical School, Istanbul, Turkey
| | - Solaf Elsayed
- Genetics, Children's Hospital, Ain Shams University, Cairo, Egypt
| | - Alain Fouilhoux
- Department of Pediatric Metabolism, Reference Center of Inherited Metabolic Disorders, Femme Mère Enfant Hospital, Lyon, France
| | - Céline Poirsier
- Genetic department, CHU-Reims, EA3801, SFR CAP santé, Reims, France
| | - Alice Goldenberg
- Department of Genetics, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F76000, Normandy Centre for Genomic and Personalized Medicine, ROUEN, France
| | - Philippe Jouvencel
- Department of Neonatology and Paediatrics, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - Alice Kuster
- Pediatric Critical Care Unit, Femme-Enfants-Adolescents Hospital, Nantes University, Nantes, France
| | | | - Leila Lazaro
- Department of Neonatology and Paediatrics, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - Samia Pichard
- Reference Centre for Inborn Errors of Metabolism, Robert-Debré University Hospital, APHP, Paris, France
| | - Serge Rivera
- Department of Neonatology and Paediatrics, Centre Hospitalier de la Côte Basque, Bayonne, France
| | - Sandrine Roche
- Department of Pediatrics, Bordeaux University Hospital, Bordeaux, France
| | | | - Agathe Roubertie
- INSERM U 1051, Institut des Neurosciences de Montpellier, Montpellier, Hérault, France.,Département de Neuropédiatrie, CHU Gui de Chauliac, Montpellier, France
| | - Sabine Sigaudy
- Genetics, Hôpital d'Enfants de la Timone, Marseille, France
| | | | - Marine Tardieu
- Department of Pediatrics, Reference Center of Inherited Metabolic Disorders, Clocheville Hospital, Tours, France
| | - Catherine Vanhulle
- Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, Rouen, France
| | - Stéphane Marret
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France.,Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, Rouen, France
| | - Soumeya Bekri
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, Normandy Center for Genomic and Personalized Medicine, Rouen, France .,Department of Metabolic Biochemistry, University Hospital Centre Rouen, Rouen, Normandie, France
| |
Collapse
|
4
|
Dabaj I, Ferey J, Marguet F, Gilard V, Basset C, Bahri Y, Brehin AC, Vanhulle C, Leturcq F, Marret S, Laquerrière A, Schmitz-Afonso I, Afonso C, Bekri S, Tebani A. Muscle metabolic remodelling patterns in Duchenne muscular dystrophy revealed by ultra-high-resolution mass spectrometry imaging. Sci Rep 2021; 11:1906. [PMID: 33479270 PMCID: PMC7819988 DOI: 10.1038/s41598-021-81090-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 01/04/2021] [Indexed: 12/11/2022] Open
Abstract
Duchenne muscular dystrophy (DMD) is a common and severe X-linked myopathy, characterized by muscle degeneration due to altered or absent dystrophin. DMD has no effective cure, and the underlying molecular mechanisms remain incompletely understood. The aim of this study is to investigate the metabolic changes in DMD using mass spectrometry-based imaging. Nine human muscle biopsies from DMD patients and nine muscle biopsies from control individuals were subjected to untargeted MSI using matrix-assisted laser desorption/ionization Fourier-transform ion cyclotron resonance mass spectrometry. Both univariate and pattern recognition techniques have been used for data analysis. This study revealed significant changes in 34 keys metabolites. Seven metabolites were decreased in the Duchenne biopsies compared to control biopsies including adenosine triphosphate, and glycerophosphocholine. The other 27 metabolites were increased in the Duchenne biopsies, including sphingomyelin, phosphatidylcholines, phosphatidic acids and phosphatidylserines. Most of these dysregulated metabolites are tightly related to energy and phospholipid metabolism. This study revealed a deep metabolic remodelling in phospholipids and energy metabolism in DMD. This systems-based approach enabled exploring the metabolism in DMD in an unprecedented holistic and unbiased manner with hypothesis-free strategies.
Collapse
Affiliation(s)
- Ivana Dabaj
- Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, 76031, Rouen, France
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000, Rouen, France
| | - Justine Ferey
- Department of Metabolic Biochemistry, Rouen University Hospital, 76031, Rouen, Cedex, France
| | - Florent Marguet
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000, Rouen, France
- Department of Pathology, Rouen University Hospital, Rouen, France
| | - Vianney Gilard
- Department of Metabolic Biochemistry, Rouen University Hospital, 76031, Rouen, Cedex, France
- Department of Neurosurgery, Rouen University Hospital, Rouen, France
| | - Carole Basset
- Department of Pathology, Rouen University Hospital, Rouen, France
| | - Youssef Bahri
- Normandie Univ, COBRA UMR 6014 Et FR 3038 Univ Rouen; INSA Rouen; CNRS IRCOF, 1 Rue TesnieÌre, 76821, Mont-Saint-Aignan Cedex, France
| | - Anne-Claire Brehin
- Department of Genetics and Reference Center for Developmental Disorders, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, 76000, Rouen, France
| | - Catherine Vanhulle
- Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, 76031, Rouen, France
| | - France Leturcq
- APHP, Laboratoire de Génétique Et Biologie Moléculaire, HUPC Cochin, Paris, France
| | - Stéphane Marret
- Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, 76031, Rouen, France
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000, Rouen, France
| | - Annie Laquerrière
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000, Rouen, France
- Department of Pathology, Rouen University Hospital, Rouen, France
| | - Isabelle Schmitz-Afonso
- Normandie Univ, COBRA UMR 6014 Et FR 3038 Univ Rouen; INSA Rouen; CNRS IRCOF, 1 Rue TesnieÌre, 76821, Mont-Saint-Aignan Cedex, France
| | - Carlos Afonso
- Normandie Univ, COBRA UMR 6014 Et FR 3038 Univ Rouen; INSA Rouen; CNRS IRCOF, 1 Rue TesnieÌre, 76821, Mont-Saint-Aignan Cedex, France
| | - Soumeya Bekri
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000, Rouen, France.
- Department of Metabolic Biochemistry, Rouen University Hospital, 76031, Rouen, Cedex, France.
| | - Abdellah Tebani
- Department of Metabolic Biochemistry, Rouen University Hospital, 76031, Rouen, Cedex, France
| |
Collapse
|
5
|
Audic F, de la Banda MGG, Bernoux D, Ramirez-Garcia P, Durigneux J, Barnerias C, Isapof A, Cuisset JM, Cances C, Richelme C, Vuillerot C, Laugel V, Ropars J, Altuzarra C, Espil-Taris C, Walther-Louvier U, Sabouraud P, Chouchane M, Vanhulle C, Trommsdorff V, Pervillé A, Testard H, Lagrue E, Sarret C, Avice AL, Beze-Beyrie P, Pauly V, Quijano-Roy S, Chabrol B, Desguerre I. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet J Rare Dis 2020; 15:148. [PMID: 32532349 PMCID: PMC7291731 DOI: 10.1186/s13023-020-01414-8] [Citation(s) in RCA: 54] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Accepted: 05/18/2020] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord. Nusinersen has been covered by public healthcare in France since May 2017. The aim of this article is to report results after 1 year of treatment with intrathecal nusinersen in children with SMA types 1 and 2 in France. Comparisons between treatment onset (T0) and after 1 year of treatment (Y1) were made in terms of motor function and need for nutritional and ventilatory support. Motor development milestone achievements were evaluated using the modified Hammersmith Infant Neurologic Examination-Part 2 (HINE-2) for patients under 2 years of age and Motor Function Measure (MFM) scores for patients over 2 years of age. RESULTS Data on 204 SMA patients (type 1 or 2) were retrospectively collected from the 23 French centers for neuromuscular diseases. One hundred and twenty three patients had been treated for at least 1 year and were included, 34 of whom were classified as type 1 (10 as type 1a/b and 24 as type 1c) and 89 as type 2. Survival motor Neuron 2 (SMN2) copy numbers were available for all but 6 patients. Patients under 2 years of age (n = 30), had significantly higher HINE-2 scores at year 1 than at treatment onset but used more nutritional and ventilatory support. The 68 patients over 2 years of age evaluated with the Motor Function Measure test had significantly higher overall scores after 1 year, indicating that their motor function had improved. The scores were higher in the axial and proximal motor function (D2) and distal motor function (D3) parts of the MFM scale, but there was no significant difference for standing and transfer scores (D1). No child in either of the two groups achieved walking. CONCLUSION Nusinersen offers life-changing benefits for children with SMA, particularly those with more severe forms of the disorder. Caregiver assessments are positive. Nevertheless, patients remain severely disabled and still require intensive support care. This new treatment raises new ethical challenges.
Collapse
Affiliation(s)
- Frédérique Audic
- Centre de Référence des Maladies Neuromusculaires de l'enfant PACARARE, Service de Neuropédiatrie, Hôpital Timone Enfants, 264 rue Saint Pierre, 13385, Marseille Cedex 5, France.
| | - Marta Gomez Garcia de la Banda
- Centre de Référence des Maladies Neuromusculaires Nord/Ile de France/Est, Hôpital Raymond Poincaré, APHP, Garches, France
| | - Delphine Bernoux
- Centre de Référence des Maladies Neuromusculaires de l'enfant PACARARE, Service de Neuropédiatrie, Hôpital Timone Enfants, 264 rue Saint Pierre, 13385, Marseille Cedex 5, France
| | - Paola Ramirez-Garcia
- Centre de Référence des Maladies Neuromusculaires de l'enfant PACARARE, Service de Neuropédiatrie, Hôpital Timone Enfants, 264 rue Saint Pierre, 13385, Marseille Cedex 5, France
| | - Julien Durigneux
- Centre de Référence des Maladies Neuromusculaires AOC, CHU d'Angers, Angers, France
| | - Christine Barnerias
- Centre de Référence des Maladies Neuromusculaires Nord/Ile de France/Est, Service de Neurologie pédiatrique, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Arnaud Isapof
- Centre de Référence des Maladies Neuromusculaires Nord/Ile de France/Est, Service de Neuropédiatrie, Hôpital Trousseau, APHP, Paris, France
| | - Jean-Marie Cuisset
- Centre de Référence des Maladies Neuromusculaires Nord/Ile de France/Est, Service de Neuropédiatrie, Hôpital Salengro CHU Lille, Lille, France
| | - Claude Cances
- Centre de Référence des Maladies Neuromusculaires AOC, Unité de Neurologie Pédiatrique, Hôpital des Enfants CHU Toulouse, Toulouse, France
| | - Christian Richelme
- Centre de Référence des Maladies Neuromusculaires PACARARE, Hôpitaux Pédiatriques de Nice CHU - Lenval, Nice, France
| | - Carole Vuillerot
- Centre de Référence des Maladies Neuromusculaires de l'enfant PACARARE, Service de MPR pédiatrique L'Escale Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France
| | - Vincent Laugel
- Centre de Référence des Maladies Neuromusculaires Nord/Ile de France/Est, Pédiatrie médico-chirurgicale, CHU de Strasbourg - Hôpital de Hautepierre, Strasbourg, France
| | - Juliette Ropars
- Centre de Référence des Maladies Neuromusculaires AOC, Service de Pédiatrie, CHRU de Brest, Brest, France
| | - Cécilia Altuzarra
- Centre de compétences des Maladies Neuromusculaires Nord/Ile de France/Est, Unité de Neuropédiatrie et médecine pédiatrique, Hôpital Minjoz, CHU de Besançon, Besançon, France
| | - Caroline Espil-Taris
- Centre de Référence des Maladies Neuromusculaires AOC, Unité de Neurologie pédiatrique, CHU Pellegrin, Bordeaux, France
| | - Ulrike Walther-Louvier
- Centre de Référence des Maladies Neuromusculaires AOC, Service de Neuropédiatrie CHU Montpellier, Montpellier, France
| | - Pascal Sabouraud
- Centre de Référence des Maladies Neuromusculaires Nord/Ile de France/Est, Site Reims enfant AMH, CHU Reims, Reims, France
| | - Mondher Chouchane
- Centre de Compétence des Maladies Neuromusculaires Nord/Ile de France/Est, Service de pédiatrie 1, Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France
| | - Catherine Vanhulle
- Centre de Compétence des Maladies Neuromusculaires Nord/Ile de France/Est, CHU de Rouen Charles Nicolle, Rouen, France
| | - Valérie Trommsdorff
- Centre de Référence des Maladies Neuromusculaires PACARARE, Service de Pédiatrie, CHU La Réunion, Saint-Pierre, France
| | - Anne Pervillé
- Centre de Compétence des Maladies Neuromusculaires PACARARE, Service de Pédiatrie, CHU La Réunion, Saint-Denis, France
| | - Hervé Testard
- Centre de Compétence des Maladies Neuromusculaires PACARARE, Neuropédiatrie, Clinique Universitaire Pédiatrique, Hôpital Couple Enfant - CHU Grenoble, Grenoble, France
| | - Emmanuelle Lagrue
- Centre de Compétence des Maladies Neuromusculaires AOC, Hôpital Clocheville, Service « Neuropédiatrie et Handicaps », Tours, France
| | - Catherine Sarret
- Centre de Référence des Maladies Neuromusculaires PACARARE, Centre hospitalo-universitaire de Clermont-Ferrand, Clermont-Ferrand, France
| | - Anne-Laude Avice
- Centre de Référence des Maladies Neuromusculaires Nord/Ile de France/Est, Nancy, Hôpital de Brabois, Vandœuvre-Lès, Nancy, France
| | | | - Vanessa Pauly
- Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS) EA 3279, Faculté de Médecine, Aix-Marseille Université, Marseille, France
| | - Susana Quijano-Roy
- Centre de Référence des Maladies Neuromusculaires Nord/Ile de France/Est, Hôpital Raymond Poincaré, APHP, Garches, France
| | - Brigitte Chabrol
- Centre de Référence des Maladies Neuromusculaires de l'enfant PACARARE, Service de Neuropédiatrie, Hôpital Timone Enfants, 264 rue Saint Pierre, 13385, Marseille Cedex 5, France
| | - Isabelle Desguerre
- Centre de Référence des Maladies Neuromusculaires Nord/Ile de France/Est, Service de Neurologie pédiatrique, Hôpital Necker-Enfants Malades, APHP, Paris, France
| |
Collapse
|
6
|
Hully M, Barnerias C, Chabalier D, Le Guen S, Germa V, Deladriere E, Vanhulle C, Cuisset JM, Chabrol B, Cances C, Vuillerot C, Espil C, Mayer M, Nougues MC, Sabouraud P, Lefranc J, Laugel V, Rivier F, Louvier UW, Durigneux J, Napuri S, Sarret C, Renouil M, Masurel A, Viallard ML, Desguerre I. Palliative Care in SMA Type 1: A Prospective Multicenter French Study Based on Parents' Reports. Front Pediatr 2020; 8:4. [PMID: 32133329 PMCID: PMC7039815 DOI: 10.3389/fped.2020.00004] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Accepted: 01/07/2020] [Indexed: 01/30/2023] Open
Abstract
Spinal muscular atrophy type 1 (SMA-1) is a severe neurodegenerative disorder, which in the absence of curative treatment, leads to death before 1 year of age in most cases. Caring for these short-lived and severely impaired infants requires palliative management. New drugs (nusinersen) have recently been developed that may modify SMA-1 natural history and thus raise ethical concerns about the appropriate level of care for patients. The national Hospital Clinical Research Program (PHRC) called "Assessment of clinical practices of palliative care in children with Spinal Muscular Atrophy Type 1 (SMA-1)" was a multicenter prospective study conducted in France between 2012 and 2016 to report palliative practices in SMA-1 in real life through prospective caregivers' reports about their infants' management. Thirty-nine patients were included in the prospective PHRC (17 centers). We also studied retrospective data regarding management of 43 other SMA-1 patients (18 centers) over the same period, including seven treated with nusinersen, in comparison with historical data from 222 patients previously published over two periods of 10 years (1989-2009). In the latest period studied, median age at diagnosis was 3 months [0.6-10.4]. Seventy-seven patients died at a median 6 months of age[1-27]: 32% at home and 8% in an intensive care unit. Eighty-five percent of patients received enteral nutrition, some through a gastrostomy (6%). Sixteen percent had a non-invasive ventilation (NIV). Seventy-seven percent received sedative treatment at the time of death. Over time, palliative management occurred more frequently at home with increased levels of technical supportive care (enteral nutrition, oxygenotherapy, and analgesic and sedative treatments). No statistical difference was found between the prospective and retrospective patients for the last period. However, significant differences were found between patients treated with nusinersen vs. those untreated. Our data confirm that palliative care is essential in management of SMA-1 patients and that parents are extensively involved in everyday patient care. Our data suggest that nusinersen treatment was accompanied by significantly more invasive supportive care, indicating that a re-examination of standard clinical practices should explicitly consider what treatment pathways are in infants' and caregivers' best interest. This study was registered on clinicaltrials.gov under the reference NCT01862042 (https://clinicaltrials.gov/ct2/show/study/NCT01862042?cond=SMA1&rank=8).
Collapse
Affiliation(s)
- Marie Hully
- Pediatric Neurology Department, Necker-Enfants Malades Hospital, APHP, Paris, France.,Physical Rehabilitation Department, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - Christine Barnerias
- Pediatric Neurology Department, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - Delphine Chabalier
- Pediatric Neurology Department, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - Sophie Le Guen
- Clinical Research Department, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - Virginie Germa
- Physical Rehabilitation Department, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - Elodie Deladriere
- Physical Rehabilitation Department, Necker-Enfants Malades Hospital, APHP, Paris, France
| | | | - Jean-Marie Cuisset
- Pediatric Neurology Department and Neuromuscular Diseases Reference Center, CHU, Lille, France
| | - Brigitte Chabrol
- Pediatric Neurology Department, La Timone Hospital, APHM, Marseille, France
| | - Claude Cances
- Pediatric Neurology Department, Enfants Hospital, Toulouse, France
| | - Carole Vuillerot
- Pediatric Physical Rehabilitation Department, Femme Mère Enfants Hospital, Bron, France
| | - Caroline Espil
- Pediatric Neurology Department, Pellegrin Hospital, Bordeaux, France
| | - Michele Mayer
- Pediatric Neurology Department, Armand Trousseau Hospital, APHP, Paris, France
| | | | | | - Jeremie Lefranc
- Pediatric Neurology Department, Morvan Hospital, Brest, France
| | - Vincent Laugel
- Pediatric Neurology Department, Hautepierre Hospital, Strasbourg, France
| | - Francois Rivier
- Pediatric Neurology Department & Neuromuscular Diseases Reference Center AOC, CHU Montpellier, PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France
| | - Ulrike Walther Louvier
- Pediatric Neurology Department & Neuromuscular Diseases Reference Center AOC, CHU Montpellier, Montpellier, France
| | - Julien Durigneux
- Pediatric Neurology Department, University Hospital, Angers, France
| | - Sylvia Napuri
- Pediatric Department, South Hospital, Rennes, France
| | - Catherine Sarret
- Pediatric Department, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Michel Renouil
- Pediatric Department, St-Pierre Hospital, Saint-Denis, France
| | - Alice Masurel
- Genetic Department, Children Hospital, CHU Dijon, Dijon, France
| | - Marcel-Louis Viallard
- Palliative Care Team, Necker-Enfants Malades Hospital, APHP, Paris, France.,Research Team "ETRES", UMR des Cordeliers, Université de Paris, Paris, France
| | - Isabelle Desguerre
- Pediatric Neurology Department, Necker-Enfants Malades Hospital, APHP, Paris, France
| |
Collapse
|
7
|
Marguet F, Rendu J, Vanhulle C, Bedat-Millet AL, Brehin AC, Fauré J, Laquerrière A. Association of fingerprint bodies with rods in a case with mutations in the LMOD3 gene. Neuromuscul Disord 2019; 30:207-212. [PMID: 32008911 DOI: 10.1016/j.nmd.2019.12.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 12/09/2019] [Accepted: 12/16/2019] [Indexed: 12/19/2022]
Abstract
Fingerprint bodies are observed in a variety of clinical situations with no definite genetic cause identified so far. We report for the first time the association of fingerprint bodies with rods in a patient who developed a slowly progressive myopathy affecting the face and limb extremities. Ultrastructural examination first disclosed fingerprint bodies and on a second biopsy, associated cytoplasmic bodies and rods. Next Generation Sequencing panel of congenital nemaline myopathy genes allowed the identification of two novel variants, a deleterious missense variant (c.1628G>T, p.Arg543Leu) located in the WASP-homology 2 domain, and a deletion (c.366delG, p.Lys122AsnFs*6) in the LMOD3 gene, generally causing severe nemaline myopathy with antenatal onset and early death. Recently, a less severe phenotype similar to our case has been reported. Our study confirms the existence of milder phenotypes linked to LMOD3 mutations and underlines that fingerprint bodies, though not specific, may be an early ultrastructural marker that could be linked, among others, to nemaline myopathy.
Collapse
Affiliation(s)
- Florent Marguet
- Department of Pathology, Normandie University, UNIROUEN, INSERM U1245, Rouen University Hospital, F76000 Rouen, France
| | - John Rendu
- Grenoble Institut Neurosciences, University of Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, 38000 Grenoble, France
| | - Catherine Vanhulle
- Department of Neonatal Pediatrics and Intensive Care, Rouen University Hospital, F76000 Rouen, France
| | | | - Anne Claire Brehin
- Department of Medical Genetics, Rouen University Hospital, F76000 Rouen, France
| | - Julien Fauré
- Grenoble Institut Neurosciences, University of Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, 38000 Grenoble, France
| | - Annie Laquerrière
- Department of Pathology, Normandie University, UNIROUEN, INSERM U1245, Rouen University Hospital, F76000 Rouen, France.
| |
Collapse
|
8
|
Lagrue E, Dogan C, De Antonio M, Audic F, Bach N, Barnerias C, Bellance R, Cances C, Chabrol B, Cuisset JM, Desguerre I, Durigneux J, Espil C, Fradin M, Héron D, Isapof A, Jacquin-Piques A, Journel H, Laroche-Raynaud C, Laugel V, Magot A, Manel V, Mayer M, Péréon Y, Perrier-Boeswillald J, Peudenier S, Quijano-Roy S, Ragot-Mandry S, Richelme C, Rivier F, Sabouraud P, Sarret C, Testard H, Vanhulle C, Walther-Louvier U, Gherardi R, Hamroun D, Bassez G. A large multicenter study of pediatric myotonic dystrophy type 1 for evidence-based management. Neurology 2019; 92:e852-e865. [DOI: 10.1212/wnl.0000000000006948] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Accepted: 10/18/2018] [Indexed: 12/18/2022] Open
Abstract
ObjectiveTo genotypically and phenotypically characterize a large pediatric myotonic dystrophy type 1 (DM1) cohort to provide a solid frame of data for future evidence-based health management.MethodsAmong the 2,697 patients with genetically confirmed DM1 included in the French DM-Scope registry, children were enrolled between January 2010 and February 2016 from 24 centers. Comprehensive cross-sectional analysis of most relevant qualitative and quantitative variables was performed.ResultsWe studied 314 children (52% females, with 55% congenital, 31% infantile, 14% juvenile form). The age at inclusion was inversely correlated with the CTG repeat length. The paternal transmission rate was higher than expected, especially in the congenital form (13%). A continuum of highly prevalent neurodevelopmental alterations was observed, including cognitive slowing (83%), attention deficit (64%), written language (64%), and spoken language (63%) disorders. Five percent exhibited autism spectrum disorders. Overall, musculoskeletal impairment was mild. Despite low prevalence, cardiorespiratory impairment could be life-threatening, and frequently occurred early in the first decade (25.9%). Gastrointestinal symptoms (27%) and cataracts (7%) were more frequent than expected, while endocrine or metabolic disorders were scarce.ConclusionsThe pedDM-Scope study details the main genotype and phenotype characteristics of the 3 DM1 pediatric subgroups. It highlights striking profiles that could be useful in health care management (including transition into adulthood) and health policy planning.
Collapse
|
9
|
Bouchat S, Verdikt R, Delacourt N, Vanhulle C, Van Driessche B, Darcis G, Pasternak A, Avettand-Fenoel V, Necsoi C, Ledouce V, Bendoumou M, Schwartz C, De Wit S, Saez-Cirion A, Berkhout B, Gautier V, Rouzioux C, Rohr O, Van Lint C. O2 Identification of a new factor involved in DNA methylation-mediated repression of latent HIV-1. J Virus Erad 2017. [DOI: 10.1016/s2055-6640(20)30818-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
10
|
Béhin A, Acquaviva-Bourdain C, Souvannanorath S, Streichenberger N, Attarian S, Bassez G, Brivet M, Fouilhoux A, Labarre-Villa A, Laquerrière A, Pérard L, Kaminsky P, Pouget J, Rigal O, Vanhulle C, Eymard B, Vianey-Saban C, Laforêt P. Multiple acyl-CoA dehydrogenase deficiency (MADD) as a cause of late-onset treatable metabolic disease. Rev Neurol (Paris) 2016; 172:231-41. [PMID: 27038534 DOI: 10.1016/j.neurol.2015.11.008] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2015] [Revised: 11/11/2015] [Accepted: 11/15/2015] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Late-onset multiple acyl-CoA dehydrogenase deficiency (MADD) is a rare, treatable, beta-oxidation disorder responsible for neuromuscular symptoms in adults. This case series describes the clinical and biochemical features of 13 French patients with late-onset MADD. METHODS AND RESULTS Thirteen ambulant patients (eight women, five men), with a median age at onset of 27 years, initially experienced exercise intolerance (n=9), isolated muscle weakness (n=1) and a multisystemic pattern with either central nervous system or hepatic dysfunction (n=3). During the worsening period, moderate rhabdomyolysis (n=5), a pseudomyasthenic pattern (n=5) and acute respiratory failure (n=1) have been observed. Weakness typically affected the proximal limbs and axial muscles, and there was sometimes facial asymmetry (n=3). Moderate respiratory insufficiency was noted in one case. Median baseline creatine kinase was 190IU/L. Lactacidemia was sometimes moderately increased at rest (3/10) and after exercise (1/3). The acylcarnitine profile was characteristic, with increases in all chain-length acylcarnitine species. Electromyography revealed a myogenic pattern, while muscle biopsy showed lipidosis, sometimes with COX-negative fibers (n=2). The mitochondrial respiratory chain was impaired in five cases, with coenzyme Q10 decreased in two cases. All patients harbored mutations in the ETFDH gene (four homozygous, seven compound heterozygous, two single heterozygous), with nine previously unidentified mutations. All patients were good responders to medical treatment, but exercise intolerance and/or muscular weakness persisted in 11 of them. CONCLUSION Late-onset forms of MADD may present as atypical beta-oxidation disorders. Acylcarnitine profiling and muscle biopsy remain the most decisive investigations for assessing the diagnosis. These tests should thus probably be performed more widely, particularly in unexplained cases of neuromuscular and multisystemic disorders.
Collapse
Affiliation(s)
- A Béhin
- AP-HP, Centre de Référence de Pathologie Neuromusculaire Paris-Est, Groupe Hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
| | - C Acquaviva-Bourdain
- Centre de Référence des Maladies Héréditaires du Métabolisme, Inserm U820, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, 69500 Bron, France
| | - S Souvannanorath
- AP-HP, Centre de Référence de Pathologie Neuromusculaire Paris-Est, Groupe Hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - N Streichenberger
- Service de Neuropathologie, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Université Claude Bernard Lyon I, 69500 Bron, France
| | - S Attarian
- AP-HM, Centre de Référence des Maladies Neuromusculaires et de la SLA, CHU de La Timone, 13005 Marseille, France
| | - G Bassez
- AP-HP, Centre de Référence de Pathologie Neuromusculaire Paris-Ouest, CHU Henri-Mondor, Créteil, France
| | - M Brivet
- AP-HP, Centre de Référence des Maladies Héréditaires du Métabolisme, Hôpital Robert-Debré, 75020 Paris, France
| | - A Fouilhoux
- Centre de Référence lyonnais des Maladies Héréditaires du Métabolisme, Groupement Hospitalier Est, Hôpital Femme Mère-Enfant, CHU de Lyon, 69500 Bron, France
| | - A Labarre-Villa
- Centre de Référence Rhône-Alpes des Maladies Neuromusculaires, CHU de Grenoble, 38000 Grenoble, France
| | - A Laquerrière
- Service d'Anatomie et Cytologie pathologiques, CHU de Rouen, 76000 Rouen, France
| | - L Pérard
- Service de Médecine Interne, Hôpital Édouard-Herriot, 69437 Lyon cedex 03, France
| | - P Kaminsky
- Centre de Référence des Maladies Neuromusculaires, CHU de Nancy (Hôpitaux de Brabois), 54500 Vandœuvre-Lès-Nancy, France
| | - J Pouget
- AP-HM, Centre de Référence des Maladies Neuromusculaires et de la SLA, CHU de La Timone, 13005 Marseille, France
| | - O Rigal
- AP-HP, Centre de Référence des Maladies Héréditaires du Métabolisme, Hôpital Robert-Debré, 75020 Paris, France
| | - C Vanhulle
- Centre de Compétences Pathologies Neuromusculaires Enfants, Néonatalogie et Réanimation Pédiatrique, CHU de Rouen, 76000 Rouen, France
| | - B Eymard
- AP-HP, Centre de Référence de Pathologie Neuromusculaire Paris-Est, Groupe Hospitalier Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - C Vianey-Saban
- Centre de Référence des Maladies Héréditaires du Métabolisme, Inserm U820, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, 69500 Bron, France
| | - P Laforêt
- AP-HP, Service de Biochimie, Hôpital de Bicêtre, 94270 Le Kremlin-Bicêtre, France
| |
Collapse
|
11
|
Melot A, Labarre A, Vanhulle C, Rondeau S, Brasseur M, Gilard V, Castel H, Marret S, Proust F. Neurodevelopmental long-term outcome in children with hydrocephalus requiring neonatal surgical treatment. Neurochirurgie 2016; 62:94-9. [PMID: 26853800 DOI: 10.1016/j.neuchi.2015.10.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2015] [Revised: 09/06/2015] [Accepted: 10/18/2015] [Indexed: 11/18/2022]
Abstract
PURPOSE To assess long-term neurodevelopmental outcome in children with hydrocephalus requiring neurosurgical treatment during the neonatal period. METHODS This prospective longitudinal population-based study included 43 children with neonatal shunted hydrocephalus. The 43 children were prospectively reviewed in the presence of their parents at the outpatient clinic. Cognitive and motor outcomes were assessed respectively using different Wechsler scales according to age and Gross Motor Function Classification System (GMFCS). Postoperative MRI was routinely performed. RESULTS The mean gestational age at birth of the 43 consecutive children with neonatal hydrocephalus (sex ratio M/F: 1.39) was 34.5±5.4 weeks of gestation. At mean follow-up of 10.4±4 years, mean total IQ was 73±27.7, with equivalent results in mean verbal and mean performance IQ. Of the 33 children with IQ evaluation, 18 presented an IQ≥85 (41.9%). Efficiency in walking without a mobility device (GMFCS≤2) was obtained in 37 children (86%). Only severity of postoperative ventricular dilation was significantly associated with unfavorable outcome (Evans index>0.37; odds ratio: 0.16, P=0.03). CONCLUSION This information could be provided to those families concerned who often experience anxiety when multi-disciplinary management of neonatal hydrocephalus is required.
Collapse
Affiliation(s)
- A Melot
- Department of Neurosurgery, Marseille University Hospital, 13000 Marseille, France
| | - A Labarre
- Department of Neonatal Pediatrics, Rouen University Hospital, 76000 Rouen, France; Region-Inserm Team (ERI 28) "Neovasc", Microvascular Endothelium and Perinatal Cerebral Lesions, Institute for Biomedical Research and Innovation, School of Medicine, Rouen University, 76000 Rouen, France
| | - C Vanhulle
- Department of Neonatal Pediatrics, Rouen University Hospital, 76000 Rouen, France
| | - S Rondeau
- Department of Neonatal Pediatrics, Rouen University Hospital, 76000 Rouen, France
| | - M Brasseur
- Department of Pediatric Radiology, Rouen University Hospital, 76000 Rouen, France
| | - V Gilard
- Department of Neurosurgery, Rouen University Hospital, 76000 Rouen, France
| | - H Castel
- INSERM U982, Neuronal and Neuroendocrine Communication and Differentiation, Rouen University, 76000 Rouen, France
| | - S Marret
- Department of Neonatal Pediatrics, Rouen University Hospital, 76000 Rouen, France; Region-Inserm Team (ERI 28) "Neovasc", Microvascular Endothelium and Perinatal Cerebral Lesions, Institute for Biomedical Research and Innovation, School of Medicine, Rouen University, 76000 Rouen, France
| | - F Proust
- Neurosurgery Department, Strasbourg University Hospital, Hautepierre Hospital, 1, avenue Molière, 67098 Strasbourg, France.
| |
Collapse
|
12
|
Marguet F, Laquerrière A, Goldenberg A, Guerrot AM, Quenez O, Flahaut P, Vanhulle C, Dumant-Forest C, Charbonnier F, Vezain M, Bekri S, Tournier I, Frébourg T, Nicolas G. Clinical and pathologic features of Aicardi-Goutières syndrome due to anIFIH1mutation: A pediatric case report. Am J Med Genet A 2016; 170A:1317-24. [DOI: 10.1002/ajmg.a.37577] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Accepted: 01/14/2016] [Indexed: 11/09/2022]
Affiliation(s)
- Florent Marguet
- Pathology Laboratory; Rouen University Hospital; Rouen France
- ERI28 “NeoVasc”; Laboratory of Microvascular Endothelium and Neonatal Brain Lesions; Rouen Institute for Biomedical Research; University of Rouen; Rouen France
| | - Annie Laquerrière
- Pathology Laboratory; Rouen University Hospital; Rouen France
- ERI28 “NeoVasc”; Laboratory of Microvascular Endothelium and Neonatal Brain Lesions; Rouen Institute for Biomedical Research; University of Rouen; Rouen France
| | - Alice Goldenberg
- Department of Genetics; Rouen University Hospital; Rouen France
- Normandy Centre for Genomic Medicine and Personalized Medicine; Rouen France
| | - Anne-Marie Guerrot
- Department of Genetics; Rouen University Hospital; Rouen France
- Normandy Centre for Genomic Medicine and Personalized Medicine; Rouen France
| | - Olivier Quenez
- Normandy Centre for Genomic Medicine and Personalized Medicine; Rouen France
- CNR-MAJ; Rouen University Hospital; Rouen France
- Inserm U1079; IRIB; Normandie Univ; Rouen France
| | - Philippe Flahaut
- Department of Paediatrics; Rouen University Hospital; Rouen France
| | | | | | - Françoise Charbonnier
- Normandy Centre for Genomic Medicine and Personalized Medicine; Rouen France
- Inserm U1079; IRIB; Normandie Univ; Rouen France
- IRIB Genomics Facility; IRIB; Normandie Univ; Rouen France
| | - Myriam Vezain
- Normandy Centre for Genomic Medicine and Personalized Medicine; Rouen France
- Inserm U1079; IRIB; Normandie Univ; Rouen France
- IRIB Genomics Facility; IRIB; Normandie Univ; Rouen France
| | - Soumeya Bekri
- ERI28 “NeoVasc”; Laboratory of Microvascular Endothelium and Neonatal Brain Lesions; Rouen Institute for Biomedical Research; University of Rouen; Rouen France
- Department of Metabolic Biochemistry; Rouen University Hospital; Rouen France
| | - Isabelle Tournier
- Normandy Centre for Genomic Medicine and Personalized Medicine; Rouen France
- Inserm U1079; IRIB; Normandie Univ; Rouen France
- IRIB Genomics Facility; IRIB; Normandie Univ; Rouen France
| | - Thierry Frébourg
- Department of Genetics; Rouen University Hospital; Rouen France
- Normandy Centre for Genomic Medicine and Personalized Medicine; Rouen France
- Inserm U1079; IRIB; Normandie Univ; Rouen France
- IRIB Genomics Facility; IRIB; Normandie Univ; Rouen France
| | - Gaël Nicolas
- Department of Genetics; Rouen University Hospital; Rouen France
- Normandy Centre for Genomic Medicine and Personalized Medicine; Rouen France
- Inserm U1079; IRIB; Normandie Univ; Rouen France
- IRIB Genomics Facility; IRIB; Normandie Univ; Rouen France
| |
Collapse
|
13
|
Van Lint C, Bouchat S, Delacourt N, Kula A, Darcis G, Corazza F, Gatot J, Melard A, Vanhulle C, Van Driessche B, Kabeya K, Pardons M, Avettand-Fenoel V, Clumeck N, De Wit S, Rohr O, Rouzioux C. Sequential treatment with 5-aza-2′deoxycitidine and deacetylase inhibitors reactivates HIV. J Virus Erad 2015. [DOI: 10.1016/s2055-6640(20)31409-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
14
|
Servais L, Montus M, Guiner CL, Ben Yaou R, Annoussamy M, Moraux A, Hogrel JY, Seferian AM, Zehrouni K, Le Moing AG, Gidaro T, Vanhulle C, Laugel V, Butoianu N, Cuisset JM, Sabouraud P, Cances C, Klein A, Leturcq F, Moullier P, Voit T. Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype. J Neuromuscul Dis 2015; 2:269-279. [PMID: 27858743 PMCID: PMC5240539 DOI: 10.3233/jnd-150100] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
BACKGROUND Exon skipping therapy is an emerging approach in Duchenne Muscular Dystrophy (DMD). Antisense oligonucleotides that induce skipping of exon 51, 44, 45, or 53 are currently being evaluated in clinical trials. These trials were designed on the basis of data available in general DMD population. OBJECTIVES Our objective was to compare the clinical and functional statuses of non-ambulant DMD patients theoretically treatable by exon 53 skipping and of DMD patients with other mutations. METHODS We first compared fifteen non-ambulant DMD patients carrying deletions theoretically treatable by exon 53 skipping (DMD-53) with fifteen closely age-matched DMD patients with mutations not treatable by exon 53 skipping (DMD-all-non-53) then with fifteen DMD patients carrying deletions not treatable by exon 53 skipping (DMD-del-non-53). RESULTS We found that DMD-53 patients had a lower left ventricular ejection fraction, more contractures and they tend to have weaker grips and pinch strengths than other DMD patients. DMD-53 patients lost ambulation significantly younger than other DMD patients. This result was confirmed by comparing ages at loss of ambulation in all non-ambulant DMD patients of the DMD cohort identified in a molecular diagnostic lab. CONCLUSIONS These prospective and retrospective data demonstrate that DMD-53 patients have clinically more severe phenotypes than other DMD patients.
Collapse
Affiliation(s)
- Laurent Servais
- Institut de Myologie, Groupe hospitalier La Pitié Salpêtrière, AP-HP, Paris, France
| | | | - Caroline Le Guiner
- Généthon, Evry, France
- Atlantic Gene Therapies, INSERM UMR, Nantes, France
| | - Rabah Ben Yaou
- Institut de Myologie, Groupe hospitalier La Pitié Salpêtrière, AP-HP, Paris, France
- Laboratoire de biochimie et génétique moléculaire, Hôpital Cochin, APHP, Paris, France
| | - Mélanie Annoussamy
- Institut de Myologie, Groupe hospitalier La Pitié Salpêtrière, AP-HP, Paris, France
| | - Amélie Moraux
- Institut de Myologie, Groupe hospitalier La Pitié Salpêtrière, AP-HP, Paris, France
| | - Jean-Yves Hogrel
- Institut de Myologie, Groupe hospitalier La Pitié Salpêtrière, AP-HP, Paris, France
| | - Andreea M. Seferian
- Institut de Myologie, Groupe hospitalier La Pitié Salpêtrière, AP-HP, Paris, France
| | - Karima Zehrouni
- Institut de Myologie, Groupe hospitalier La Pitié Salpêtrière, AP-HP, Paris, France
| | - Anne-Gaëlle Le Moing
- Institut de Myologie, Groupe hospitalier La Pitié Salpêtrière, AP-HP, Paris, France
| | - Teresa Gidaro
- Institut de Myologie, Groupe hospitalier La Pitié Salpêtrière, AP-HP, Paris, France
| | - Catherine Vanhulle
- Service de Pédiatrie, Centre Hospitalier Universitaire (CHU), Rouen, France
| | - Vincent Laugel
- Service de Pédiatrie, Centre Hospitalier Universitaire (CHU), Strasbourg, France
| | - Nina Butoianu
- Pediatric Neurology Clinic, Alexandru Obregia Hospital, Bucharest, Romania
| | - Jean-Marie Cuisset
- Service de Neuropédiatrie, Centre hospitalier régional universitaire et faculté de médecine, Lille, France
| | - Pascal Sabouraud
- Service de Pédiatrie A, Hôpital Américain, CHU de Reims, Reims, France
| | - Claude Cances
- Service de Neurologie Pédiatrique, Hôpital des Enfants, Toulouse, France
| | - Andrea Klein
- Department of pediatric neurology, University Children’s Hospital, Zurich, Switzerland
| | - France Leturcq
- Institut de Myologie, Groupe hospitalier La Pitié Salpêtrière, AP-HP, Paris, France
- Laboratoire de biochimie et génétique moléculaire, Hôpital Cochin, APHP, Paris, France
| | - Philippe Moullier
- Généthon, Evry, France
- Atlantic Gene Therapies, INSERM UMR, Nantes, France
| | - Thomas Voit
- Institut de Myologie, Groupe hospitalier La Pitié Salpêtrière, AP-HP, Paris, France
| |
Collapse
|
15
|
Rice GI, Del Toro Duany Y, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G, Bader-Meunier B, Baildam EM, Battini R, Beresford MW, Casarano M, Chouchane M, Cimaz R, Collins AE, Cordeiro NJ, Dale RC, Davidson JE, De Waele L, Desguerre I, Faivre L, Fazzi E, Isidor B, Lagae L, Latchman AR, Lebon P, Li C, Livingston JH, Lourenço CM, Mancardi MM, Masurel-Paulet A, McInnes IB, Menezes MP, Mignot C, O'Sullivan J, Orcesi S, Picco PP, Riva E, Robinson RA, Rodriguez D, Salvatici E, Scott C, Szybowska M, Tolmie JL, Vanderver A, Vanhulle C, Vieira JP, Webb K, Whitney RN, Williams SG, Wolfe LA, Zuberi SM, Hur S, Crow YJ. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 2014; 46:503-509. [PMID: 24686847 PMCID: PMC4004585 DOI: 10.1038/ng.2933] [Citation(s) in RCA: 419] [Impact Index Per Article: 41.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2014] [Accepted: 03/05/2014] [Indexed: 12/23/2022]
Abstract
The type I interferon system is integral to human antiviral immunity. However, inappropriate stimulation or defective negative regulation of this system can lead to inflammatory disease. We sought to determine the molecular basis of genetically uncharacterized cases of the type I interferonopathy Aicardi-Goutières syndrome, and of other patients with undefined neurological and immunological phenotypes also demonstrating an upregulated type I interferon response. We found that heterozygous mutations in the cytosolic double-stranded RNA receptor gene IFIH1 (MDA5) cause a spectrum of neuro-immunological features consistently associated with an enhanced interferon state. Cellular and biochemical assays indicate that these mutations confer a gain-of-function - so that mutant IFIH1 binds RNA more avidly, leading to increased baseline and ligand-induced interferon signaling. Our results demonstrate that aberrant sensing of nucleic acids can cause immune upregulation.
Collapse
Affiliation(s)
- Gillian I Rice
- Manchester Academic Health Science Centre, University of Manchester, Genetic Medicine, Manchester, UK
| | - Yoandris Del Toro Duany
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.,Boston Children's Hospital, Boston, MA 02115, USA
| | - Emma M Jenkinson
- Manchester Academic Health Science Centre, University of Manchester, Genetic Medicine, Manchester, UK
| | - Gabriella Ma Forte
- Manchester Academic Health Science Centre, University of Manchester, Genetic Medicine, Manchester, UK
| | - Beverley H Anderson
- Manchester Academic Health Science Centre, University of Manchester, Genetic Medicine, Manchester, UK
| | - Giada Ariaudo
- Child Neurology and Psychiatry Unit, C. Mondino National Neurological Institute, Pavia, Italy.,Department of Brain and Behavioral Sciences, Unit of Child Neurology and Psychiatry, University of Pavia, Pavia, Italy
| | - Brigitte Bader-Meunier
- Department of pediatric Immunology and Rheumatology, INSERM U 768, Imagine Foundation, APHP, Hôpital Necker, Paris, France
| | - Eileen M Baildam
- Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Roberta Battini
- Department of Developmental Neuroscience, IRCCS Stella Maris, Pisa, Italy
| | - Michael W Beresford
- Institute of Translational Medicine, University of Liverpool; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Manuela Casarano
- Department of Developmental Neuroscience, IRCCS Stella Maris, Pisa, Italy
| | | | | | - Abigail E Collins
- Department of Pediatrics, Division of Pediatric Neurology, University of Colorado, Denver, School of Medicine, USA
| | - Nuno Jv Cordeiro
- Department of Paediatrics, Rainbow House NHS Ayrshire & Arran, Scotland, UK
| | - Russell C Dale
- Neuroimmunology group, the Children's Hospital at Westmead, University of Sydney, Australia
| | - Joyce E Davidson
- Department of Paediatric Rheumatology, Royal Hospital for Sick Children, Glasgow, UK
| | - Liesbeth De Waele
- Department of Development and Regeneration, KU Leuven, Paediatric Neurology, University Hospitals Leuven, Leuven, Belgium
| | - Isabelle Desguerre
- Department of pediatric Immunology and Rheumatology, INSERM U 768, Imagine Foundation, APHP, Hôpital Necker, Paris, France
| | - Laurence Faivre
- Centre de Génétique, Hôpital d'Enfants, CHU de Dijon et Université de Bourgogne, Dijon, France
| | - Elisa Fazzi
- Child Neurology and Psychiatry Unit. Civil Hospital. Department of Clinical and Experimental Sciences, University of Brescia, Italy
| | - Bertrand Isidor
- Service de Génétique Médicale, Inserm, CHU Nantes, UMR-S 957, Nantes, France
| | - Lieven Lagae
- Department of Development and Regeneration, KU Leuven, Paediatric Neurology, University Hospitals Leuven, Leuven, Belgium
| | - Andrew R Latchman
- Division of General Pediatrics, Department of Pediatrics, McMaster Children's Hospital, McMaster University, Hamilton, Canada
| | - Pierre Lebon
- Université et Faculté de Medecine Paris Descartes, Paris, France
| | - Chumei Li
- Department of Pediatrics, Clinical Genetics Program, McMaster Children's Hospital, McMaster University, Hamilton, Canada
| | - John H Livingston
- Department of Paediatric Neurology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | | | | | - Alice Masurel-Paulet
- Centre de Génétique, Hôpital d'Enfants, CHU de Dijon et Université de Bourgogne, Dijon, France
| | - Iain B McInnes
- Institute of Infection Immunity and Inflammation, University of Glasgow, Glasgow, UK
| | - Manoj P Menezes
- Institute for Neuroscience and Muscle Research, the Children's Hospital at Westmead, University of Sydney, Australia
| | - Cyril Mignot
- AP-HP, Department of Genetics, Groupe Hospitalier Pitié Salpêtrière, F-75013, Paris, France
| | - James O'Sullivan
- Manchester Academic Health Science Centre, University of Manchester, Genetic Medicine, Manchester, UK
| | - Simona Orcesi
- Child Neurology and Psychiatry Unit, C. Mondino National Neurological Institute, Pavia, Italy
| | - Paolo P Picco
- Paediatric Rheumatology, Giannina Gaslini Institute, Genoa, Italy
| | - Enrica Riva
- Clinical Department of Pediatrics, San Paolo Hospital, University of Milan, Italy
| | - Robert A Robinson
- Department of Neurology, Great Ormond Street Hospital for Children, London, UK
| | - Diana Rodriguez
- AP-HP, Service de Neuropédiatrie & Centre de Référence de Neurogénétique, Hôpital A. Trousseau, HUEP, F-75012 Paris, France.,UPMC Univ Paris 06, F-75012 Paris; Inserm U676, F-75019 Paris, France
| | - Elisabetta Salvatici
- Clinical Department of Pediatrics, San Paolo Hospital, University of Milan, Italy
| | - Christiaan Scott
- University of Cape Town, Red Cross War Memorial Children's Hospital, Republic of South Africa
| | - Marta Szybowska
- Department of Pediatrics, Clinical Genetics Program, McMaster Children's Hospital, McMaster University, Hamilton, Canada
| | - John L Tolmie
- Department of Clinical Genetics, Southern General Hospital, Glasgow, Scotland, UK
| | - Adeline Vanderver
- Department of Paediatric Neurology, Children's National Medical Center, Washington DC, USA
| | - Catherine Vanhulle
- Service de Néonatalogie et Réanimation, Hôpital Charles Nicolle, CHU Rouen, F-76031 Rouen, France
| | - Jose Pedro Vieira
- Neurology Department. Hospital Dona Estefânia, Centro Hospitalar de Lisboa Central, Portugal
| | - Kate Webb
- University of Cape Town, Red Cross War Memorial Children's Hospital, Republic of South Africa
| | - Robyn N Whitney
- Division of Pediatric Neurology, Department of Pediatrics, McMaster Children's Hospital, McMaster University, Hamilton, Canada
| | - Simon G Williams
- Manchester Academic Health Science Centre, University of Manchester, Genetic Medicine, Manchester, UK
| | - Lynne A Wolfe
- NIH Undiagnosed Diseases Program, Common Fund, Office of the Director, NIH, Bethesda, MD, USA
| | - Sameer M Zuberi
- Paediatric Neurosciences Research Group, Fraser of Allander Neurosciences Unit, Royal Hospital for Sick Children, Glasgow, UK.,School of Medicine, College of Medical, Veterinary & Life Sciences, University of Glasgow, UK
| | - Sun Hur
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.,Boston Children's Hospital, Boston, MA 02115, USA
| | - Yanick J Crow
- Manchester Academic Health Science Centre, University of Manchester, Genetic Medicine, Manchester, UK
| |
Collapse
|
16
|
Abstract
Cerebral palsy (CP), defined as a group of nonprogressive disorders of movement and posture, is the most common cause of severe neurodisability in children. Understanding its physiopathology is crucial to developing some protective strategies. Interruption of oxygen supply to the fetus or brain asphyxia was classically considered to be the main causal factor explaining later CP. However several ante-, peri-, and postnatal factors could be involved in the origins of CP syndromes. Congenital malformations are rarely identified. CP is most often the result of environmental factors, which might interact with genetic vulnerabilities, and could be severe enough to cause the destructive injuries visible with standard imaging (i.e., ultrasonographic study or MRI), predominantly in the white matter in preterm infants and in the gray matter and the brainstem nuclei in full-term newborns. Moreover they act on an immature brain and could alter the remarkable series of developmental events. Biochemical key factors originating in cell death or cell process loss, observed in hypoxic-ischemic as well as inflammatory conditions, are excessive production of proinflammatory cytokines, oxidative stress, maternal growth factor deprivation, extracellular matrix modifications, and excessive release of glutamate, triggering the excitotoxic cascade. Only two strategies have succeeded in decreasing CP in 2-year-old children: hypothermia in full-term newborns with moderate neonatal encephalopathy and administration of magnesium sulfate to mothers in preterm labor.
Collapse
Affiliation(s)
- Stéphane Marret
- Department of Neonatal Medicine and Centre of Child Functional Education, Rouen University Hospital, Rouen, France; INSERM Region Team ERI 28, Rouen Institute for Medical Research and Innovation, School of Medicine, Rouen University, Rouen, France.
| | | | | |
Collapse
|
17
|
Verdure P, Le Moigne O, Massardier EG, Vanhulle C, Tollard E, Maltête D. Migraine-like headache and ocular malformations may herald Moyamoya syndrome. Rev Neurol (Paris) 2012; 168:460-1. [PMID: 22425396 DOI: 10.1016/j.neurol.2011.09.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2011] [Revised: 09/21/2011] [Accepted: 09/26/2011] [Indexed: 11/19/2022]
|
18
|
Brzakala V, Debeaumont D, Nedelcu T, Abu Amara S, Vanhulle C, Lechevallier J. Contrôle de la spasticité chez l’enfant infirme moteur cérébral non marchant par la délivrance de baclofène par voie intrathécale. À propos de 11 cas. ACTA ACUST UNITED AC 2009. [DOI: 10.1016/j.rcot.2009.04.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Lechevallier J, Brzakala V, Vanhulle C, Abu Amara S. SOFOP-14 – Chirurgie orthopédique – Contrôle de la spasticité chez l’enfant non marchant par pompe à Baclofène intra-thécal. Arch Pediatr 2008. [DOI: 10.1016/s0929-693x(08)72394-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Van Lint C, Quivy V, Demonté D, Chariot A, Vanhulle C, de Walque S, Gaudray G, Veithen E, Bours V, Piette J, Burny A. Molecular mechanisms involved in HIV-1 transcriptional latency and reactivation: implications for the development of therapeutic strategies. Bull Mem Acad R Med Belg 2004; 159:176-89. [PMID: 15615091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
The persistence of latently HIV-infected cellular reservoirs, despite prolonged treatment with ART (antiretroviral therapy), represents the major hurdle to virus eradication. These latently infected cells are a permanent source for virus reactivation and lead to a rebound of the viral load after interruption of ART. Therefore, a greater understanding of the molecular mechanisms regulating viral latency and reactivation should lead to rational strategies aimed at purging the latent HIV reservoirs. Our laboratory is studying elements critical for the mechanisms of viral transcriptional reactivation including: 1) the transcription factor NF-kB, which is induced by proinflammatory cytokines (such as TNFalpha) and binds to two sites kB in the HIV-1 promoter region; 2) the specific remodeling of a single nucleosome (called nuc-1 and located immediately downstream of the HIV transcription start site under latency conditions) upon activation of the HIV-1 promoter; 3) post-translational acetylation of histones and of non-histone proteins (following treatment with deacetylase inhibitors [HDACi]), which induces viral transcription and nuc-1 remodeling. Recently, we have identified a new regulatory link between the first (NF-kB) and the third (protein acetylation) element by demonstrating a strong synergistic activation of HIV-1 promoter activity by TNFalpha (an inducer of NF-kB) and HDACi. In addition to the prototypical subtype B promoter, we have observed the TNFalpha/HDACi synergism with viral promoters from subtypes A through G of the HIV-1 major group, with a positive correlation between the number of kB sites present in the respective promoters and the amplitude of the TNFalpha/HDACi synergism. Importantly, the physiological relevance of this synergism was shown on HIV-1 replication in both acutely and latently HIV-infected cell lines. Therefore, our results open new therapeutic strategies aimed at administrating deacetylase inhibitor(s) together with continuous ART in order to force viral expression and decrease the pool of latently HIV-infected cellular reservoirs.
Collapse
Affiliation(s)
- C Van Lint
- Université Libre de Bruxelles, Institut de Biologie et de Médecine Moléculaires, Service de Chimie Biologique, Gosselies, Belgium
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Marret S, Lardennois C, Mercier A, Radi S, Michel C, Vanhulle C, Charollais A, Gressens P. Fetal and neonatal cerebral infarcts. Biol Neonate 2001; 79:236-40. [PMID: 11275658 DOI: 10.1159/000047098] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Focal arterial infarction in the full-term newborn is an important cause of acquired cerebral lesions in the perinatal period. Clinical motor seizures, most often unifocal, are the nearly constant disclosing symptom confirmed by focal EEG abnormalities. A multifactorial physiopathology is usual, including genetic and perinatal environmental factors. In the past decade, various acquired or genetic thrombophilias have been discussed as risk factors. For several of the involved mechanisms, the excitotoxic cascade could represent a common final pathway leading to neuronal cell death. Early magnetic resonance imaging studies and EEG help to identify the newborns with strokes who are likely to develop hemiplegia and disabilities at school. Protection of the human fetal brain remains difficult, since the triggering factor initiating the excitotoxic cascade is rarely observed. Treatment of seizures is nevertheless necessary, because it seems that they accelerate anoxia-induced neuronal death in animal models of focal hypoxic ischemia.
Collapse
Affiliation(s)
- S Marret
- Department of Neonatal Medicine, Clinique de Pédiatrie et de Puériculture, Hôpital Charles Nicolle, Rouen, France.
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Bouhadiba Z, Dacher J, Monroc M, Vanhulle C, Ménard JF, Kalifa G. [MRI of the brain in the evaluation of children with developmental delay]. J Radiol 2000; 81:870-3. [PMID: 10916004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Abstract
PURPOSE To analyze the diagnostic value of MRI in children with developmental delay. Materials and Methods. From 1991 to 1997, 224 examinations were performed. Retrospective analysis of clinical findings and diagnostic yield was carried out. RESULTS MRI was abnormal in 109 cases. It never resulted in any patient care modification. 55 malformations, 12 cases of cerebral atrophy, 7 cases of white matter disease and 2 patients with phakomatose were identified. Myelination delay (26 cases), increased signal of posterior white matter on T2-weighted images (9 cases) or widened Virchow-Robin spaces (3 cases) were frequently encountered, but it remained unclear whether they represented normal variants or true abnormalities. Post ischemic lesions were identified in 10 cases. Frequency of abnormal studies was significantly lower in children with developmental delay and behavioral disorders than in patients with other clinical presentation. CONCLUSION Diagnostic yield of cerebral MRI can justify its performance by comparison to other imaging modalities. It should be correlated with other investigations performed in a specialized unit. Its main interest is for classification and research. Risk of sedation or anesthesia should also be taken in account. Risk can be lowered using adequately equipped MR units and organizing procedures in collaboration with anesthesiologists.
Collapse
Affiliation(s)
- Z Bouhadiba
- Service de Radiologie Pédiatrique, CHU Charles Nicolle, Rouen, France
| | | | | | | | | | | |
Collapse
|
23
|
Marret S, Eurin D, Vanhulle C, Brossard V, Marpeau L, Fessard C. [Treatment and decision tree in ante- and perinatal neurologic pathology]. Arch Pediatr 2000; 5 Suppl 2:174s-179s. [PMID: 9759253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- S Marret
- Service de médecine néonatale, hôpital Charles-Nicolle, CHU de Rouen, France
| | | | | | | | | | | |
Collapse
|
24
|
Kiernan RE, Vanhulle C, Schiltz L, Adam E, Xiao H, Maudoux F, Calomme C, Burny A, Nakatani Y, Jeang KT, Benkirane M, Van Lint C. HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J 1999; 18:6106-18. [PMID: 10545121 PMCID: PMC1171675 DOI: 10.1093/emboj/18.21.6106] [Citation(s) in RCA: 340] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The human immunodeficiency virus (HIV) trans- activator protein, Tat, stimulates transcription from the viral long-terminal repeats (LTR) through an RNA hairpin element, trans-activation responsive region (TAR). We and others have shown that trans-activator protein (Tat)-associated histone acetyltransferases (TAHs), p300 and p300/CBP-associating factor (PCAF), assist functionally in the activation of chromosomally integrated HIV-1 LTR. Here, we show that p300 and PCAF also directly acetylate Tat. We defined two sites of acetylation located in different functional domains of Tat. p300 acetylated Lys50 in the TAR RNA binding domain, while PCAF acetylated Lys28 in the activation domain of Tat. In support of a functional role for acetylation in vivo, histone deacetylase inhibitor (trichostatin A) synergized with Tat in transcriptional activation of the HIV-1 LTR. Synergism was TAR-dependent and required the intact presence of both Lys28 and Lys50. Mechanistically, acetylation at Lys28 by PCAF enhanced Tat binding to the Tat-associated kinase, CDK9/P-TEFb, while acetylation by p300 at Lys50 of Tat promoted the dissociation of Tat from TAR RNA that occurs during early transcription elongation. These data suggest that acetylation of Tat regulates two discrete and functionally critical steps in transcription, binding to an RNAP II CTD-kinase and release of Tat from TAR RNA.
Collapse
Affiliation(s)
- R E Kiernan
- Laboratoire de Virologie Moléculaire et Transfert de Gène, Institut de Génétique Humaine, UPR1142 Montpellier, 34396, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
UNLABELLED Herpes simplex encephalitis (HSE) rarely occurs in children, is not easily diagnosed, and has a poor prognosis. CASE REPORT We report a pediatric case with a relapse on the 29th day despite conventional acyclovir therapy. As the relapse mechanism is not clearly understood, antiviral and immunosuppressive therapy was administered. CONCLUSION This case underlines the importance of clinical examination and the necessity of accurate testing prior stopping antiviral treatment. A better understanding of the relapse mechanism is required in order to propose more efficient treatment.
Collapse
Affiliation(s)
- C Paillard
- Service de réanimation pédiatrique, hôpital Charles-Nicolle, Rouen, France
| | | | | | | | | | | |
Collapse
|
26
|
Lenstra ATH, Bracke B, van Dijk B, Maes S, Vanhulle C, Desseyn HO. Net Intensities: Accuracy Improvement Through a Bayesian Perspective on the Measuring Strategy and Their Persistent Lack of Precision. An Illustration. Acta Crystallogr B Struct Sci 1998. [DOI: 10.1107/s0108768198004637] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
2,3-Diketopiperazine (2,3-piperazinedione), C4H6N2O2, crystallizes in the monoclinic space group P21/c with a = 5.941 (3), b = 10.080 (3), c = 8.282 (2) Å, β = 95.87 (3)°, V = 493.4 (5) Å3, Z = 4, Dx
= 1.536 Mg m−3 and Mr
= 114.1. The six-membered ring adopts a skew-boat conformation with Q = 0.467 (3) Å, θ = 64.6 (3)° and φ = 269.8 (4)°. The C
2 symmetry, which typifies the free molecule, is broken by the formation of two intermolecular N—H...O bonds involving only one of the C=O groups of the 2,3-diketopiperazine molecule. The intensity data typical for a time series are summarized in traditional statistics by B = σ2(B) = ΣBi
and R = σ2(R) = ΣRi
, where B is the background and R the raw intensity. Exploitation of the same data using Bayesian methodology leads to similar values for B and R, but the variances for these signals are significantly smaller. This reduction in variance is dictated by the length N of the time series. With 25 observations in each hkl time series we arrive at variances that are 25% of their classical values. So, a measuring strategy in which a single observation with a slow scan at speed 1/N is preferred above a series of N observations at speed 1 produces the worst possible benefit within a fixed time frame. In complete contrast to our expectation, structure refinements reveal that that the standard deviation of an observation of unit weight, S, will converge towards its ideal unit value only when we decrease the accuracy of the data set. This unpleasant behaviour points to a serious discrepancy between accuracy and precision. Our reflection intensities are systematically wrong, because we underestimate the wavelength dispersion. On our CAD-4 equipment a sealed Mo tube and the standard graphite monochromator produce an incident beam with Δλ/λ = 14%. As a consequence, the observed background intensities are not representative of the real background. The size of the background error depends on the nearby Bragg intensity. The magnitude of the signal pollution contaminating the local background is ∼2% of the maximum Bragg intensity found at λ = 0.71 Å.
Collapse
|
27
|
Maes ST, Vanhulle C, Lenstra ATH. The Background: from Observation to a `Non-Event' in Single-Crystal Diffractometry. Acta Crystallogr A 1998. [DOI: 10.1107/s010876739701787x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
28
|
Kiermer V, Van Lint C, Briclet D, Vanhulle C, Kettmann R, Verdin E, Burny A, Droogmans L. An interferon regulatory factor binding site in the U5 region of the bovine leukemia virus long terminal repeat stimulates Tax-independent gene expression. J Virol 1998; 72:5526-34. [PMID: 9621009 PMCID: PMC110197 DOI: 10.1128/jvi.72.7.5526-5534.1998] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Bovine leukemia virus (BLV) replication is controlled by both cis- and trans-acting elements. The virus-encoded transactivator, Tax, is necessary for efficient transcription from the BLV promoter, although it is not present during the early stages of infection. Therefore, sequences that control Tax-independent transcription must play an important role in the initiation of viral gene expression. This study demonstrates that the R-U5 sequence of BLV stimulates Tax-independent reporter gene expression directed by the BLV promoter. R-U5 was also stimulatory when inserted immediately downstream from the transcription initiation site of a heterologous promoter. Progressive deletion analysis of this region revealed that a 46-bp element corresponding to the 5' half of U5 is principally responsible for the stimulation. This element exhibited enhancer activity when inserted upstream or downstream from the herpes simplex virus thymidine kinase promoter. This enhancer contains a binding site for the interferon regulatory factors IRF-1 and IRF-2. A 3-bp mutation that destroys the IRF recognition site caused a twofold decrease in Tax-independent BLV long terminal repeat-driven gene expression. These observations suggest that the IRF binding site in the U5 region of BLV plays a role in the initiation of virus replication.
Collapse
Affiliation(s)
- V Kiermer
- Department of Molecular Biology, University of Brussels, B1640 Rhode-Saint-Genèse, Belgium.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
UNLABELLED Paraplegia after repair of coarctation of the aorta is uncommon. CASE REPORT A 2-month-old boy underwent excision of the coarctation area and primary anastomosis because of persistent heart failure. Spastic paraplegia was noted some hours after surgery. Motor deficit partially improved, but bladder dysfunction appeared some months after. Medullary magnetic resonance imaging (MRI) revealed an ischemia-related narrowing of the medullary diameter. CONCLUSION Paraplegia after repair of coarctation of the aorta, described in adults and infants, is also seen in neonates. Prevention by preoperative monitoring of somatosensory evoked potentials is effective in adults, but difficult to perform in very young children.
Collapse
Affiliation(s)
- C Vanhulle
- Service de pédiatrie et génétique médicale, Hôpital Charles-Nicolle, Rouen, France
| | | | | |
Collapse
|
30
|
Abstract
BACKGROUND Stroke is a rare cause of neonatal seizures. CASE REPORTS During a 5-year period, eight full-term infants were admitted to hospital for seizures due to a stroke. Seizures began shortly after birth and were always one-sided. Early CT scans showed cerebral infarctions. Motor disabilities such as hemiparesis were found in three out of seven cases; language difficulties were observed in the same proportion; however all the children had not reached school age. CONCLUSION Neonatal localized seizures may be symptomatic of a stroke and therefore justify a computerized tomography (CT) scan. Motor and cognitive sequelae require early management.
Collapse
Affiliation(s)
- C Vanhulle
- Service de Pédiatrie et Génétique Médicale, Hôpital Charles-Nicolle, Rouen, France
| | | | | | | | | |
Collapse
|
31
|
Mouterde O, Mallet E, Vanhulle C, Chauvière G, Hévin B, Meunier M, Lenaerts C, Ginies JL, Claeyssens S, Basuyau JP. Effet thérapeutique et nutritionnel d'un soluté de réhydratation orale contenant de la glutamine. Étude multicentrique randomisée à double insu chez 44 nourrissons diarrhéiques. Arch Pediatr 1998. [DOI: 10.1016/s0929-693x(97)86873-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Marret S, Eurin D, Vanhulle C, Brossard V, Marpeau L, Fessard C. Traitements et arbre décisionnel en pathologie neurologique anté- et périnatale. Arch Pediatr 1998. [DOI: 10.1016/s0929-693x(98)81285-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Abstract
BACKGROUND Wernicke's encephalopathy is usually seen in alcoholic adults. It is rare in childhood and usually discovered in a context of several pathological events. We report here a typical case of a teenager. CASE REPORT A 15-year-old girl with acute leukemia was given chemotherapy that resulted in profound aplasia and serious infection. She exhibited abnormal eye movements, ataxia, lethargy, enuresis and amnesia. MR examination showed T2-weighted images with increased signal in the thalami (pulvinar) and periaqueducal region. The symptoms improved dramatically with thiamine therapy. Omission of the usual vitamin supplementation between the courses of chemotherapy was responsible for this encephalopathy. CONCLUSION Thiamine deficiency can lead to death or amnesia. Rapid efficacy of vitamin supplementation helps diagnosis and prevents sequelae.
Collapse
Affiliation(s)
- C Vanhulle
- Service de pédiatrie et génétique médicale, hôpital Charles-Nicolle, Rouen, France
| | | | | | | | | | | |
Collapse
|
34
|
Mouterde O, Mallet E, Vanhulle C, Chauvière G, Hévin B, Meunier M, Lenaerts C, Ginies J, Claeyssens S, Basuyau I. Effet therapeutique et nutritionnel d'un solute de rehydratation orale contenant de la glutamine. Etude multicentrique randomisee en double aveugle chez 44 nourrissons diarrheiques. Arch Pediatr 1997. [DOI: 10.1016/s0929-693x(97)86613-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Vanhulle C, Callonnec F, Fedina I, Parain D. Accidents vasculaires idiopathiques sylviens profonds. Étude au doppler transcrânien. Arch Pediatr 1996. [DOI: 10.1016/0929-693x(96)87639-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
36
|
Abstract
Actimetry in newborns is relevant if two actimeters are placed, one on each ankle. This study has been conducted on nine normal three days old newborns. It has shown an indisputable link between the lack of activity and the observed sleep during the night that was missing during the day. The longest period of wake was recorded during the day and the longest period of sleep or inactivity was during the night. This study has confirmed the existence of an ultradian rhythm of quiet sleep and wake. It is also possible that a beginning of a circadian rest-activity rhythm exists already in the neonatal period, that is still discussed in the literature.
Collapse
Affiliation(s)
- C Vanhulle
- Service de pédiatrie, centre hospitalier et universitaire de Rouen, Hôpital Charles-Nicolle, France
| | | |
Collapse
|
37
|
Bex F, Hermans P, Sprecher S, Achour A, Badjou R, Desgranges C, Cogniaux J, Franchioli P, Vanhulle C, Lachgar A. Syngeneic adoptive transfer of anti-human immunodeficiency virus (HIV-1)-primed lymphocytes from a vaccinated HIV-seronegative individual to his HIV-1-infected identical twin. Blood 1994; 84:3317-26. [PMID: 7949087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Immunotherapy by adoptive transfer of lymphocytes was attempted in identical twins, one who was virus-free and the other who was infected with human immunodeficiency virus-1 (HIV-1), at the stage of acquired immunodeficiency syndrome. The noninfected twin was vaccinated by priming with a recombinant vaccinia virus expressing the envelope glycoprotein of one of his brother's viruses and boosting with the same purified gp160 adsorbed on alum. Vaccination elicited major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes specific for HIV-1, but no antibody response. The diseased brother, a 38-year-old homosexual who had developed repeated opportunistic infections since 1990 and had a CD4+ count reduced to practically zero, was treated by infusions of lymphocytes collected from the vaccinated brother by lymphopheresis. After a first transfer of the whole lymphocyte population, no changes were observed in the clinical status and biologic or virologic parameters. A second transfer was then applied with activation of the cells with purified envelope glycoprotein before infusion. The outcome of the treatment was an increase in total lymphocytes, in CD4+ and activated CD8+ DR+ cell counts, and in proliferative responses to HIV antigens. A marked but transient 3-log increase in cellular and plasmatic virus loads was also observed after the second adoptive transfer. These observations will be considered with attention to improve the future adoptive transfer protocols, especially in patients with severe CD4+ depletion.
Collapse
Affiliation(s)
- F Bex
- Department of Molecular Biology, University of Brussels, Belgium
| | | | | | | | | | | | | | | | | | | |
Collapse
|